Outlook Therapeutics (BST:41ON) - Stock Price, News & Analysis

41ON Stock Overview

Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. More details

41ON fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings are forecast to grow 61.33% per year

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Outlook Therapeutics, Inc. Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

4SC

DB:VSC

€50.2m

Formycon

XTRA:FYB

€857.2m

Price History & Performance

Summary of all time highs, changes and price drops for Outlook Therapeutics
Historical stock prices
Current Share Price	US$7.28
52 Week High	US$31.60
52 Week Low	US$3.80
Beta	0.19
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-78.23%
5 Year Change	-68.66%
Change since IPO	-94.56%

Recent updates

Shareholder Returns

	41ON	DE Biotechs	DE Market
7D	0%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Return vs Industry: Insufficient data to determine how 41ON performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 41ON performed against the German Market.

Price Volatility

Is 41ON's price volatile compared to industry and market?
41ON volatility
41ON Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 41ON has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 41ON's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	24	Russ Trenary	www.outlooktherapeutics.com

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.

Outlook Therapeutics, Inc. Fundamentals Summary

How do Outlook Therapeutics's earnings and revenue compare to its market cap?
41ON fundamental statistics
Market cap	€171.05m
Earnings (TTM)	-€48.35m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Is 41ON overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
41ON income statement (TTM)
Revenue	US$0
Cost of Revenue	US$21.12m
Gross Profit	-US$21.12m
Other Expenses	US$30.38m
Earnings	-US$51.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.31
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-150.1%

How did 41ON perform over the long term?

See historical performance and comparison

41ON Stock Overview

Rewards

Risk Analysis

Outlook Therapeutics, Inc. Competitors

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

DB:VSC

€50.2m

XTRA:FYB

€857.2m

Price History & Performance

Recent News & Updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Recent updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Forecast breakeven pushed back to 2024

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.39

New 90-day high: €1.07

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.04

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding